HIV vaccine acceptability among high-risk drug users living in a low-prevalence community
Tuesday, November 5, 2013
Background: An HIV vaccine could substantially impact the epidemic, but adequate uptake is a concern, particularly in populations with low perceived HIV risk. This study examined HIV vaccine acceptability among high-risk drug users in a rural setting. Methods: Interviewer-administered questionnaires collected data on risk behavior and attitudes toward HIV vaccination from 347 HIV-negative drug users (70% with history of injection) enrolled in a cohort study in Appalachia. Results: Only 24% believed that they were at risk for HIV, yet 92% reported that they would accept a HIV vaccine that was 90% effective. Only 25% would accept a vaccine that was less than 90% effective. The median price respondents were willing to pay out-of-pocket for a 90% effective vaccine was $100. The most commonly cited barrier to vaccine acceptability was cost (79%), followed by requirement for multiple doses (32%), transportation and time to visit the clinic (22% and 12%, respectively), and fear that the provider would tell others about the patient's vaccination (15%). Also, 47% reported that they would be less likely to get a vaccine that caused future HIV tests to be positive. Factors that could increase uptake include oral administration (44%) and monetary incentives (64%). Many believed they would remain at risk for HIV from unprotected sex (29%) or equipment-sharing (41%) if they received a 90% effective vaccine. Conclusions: Despite low perceived risk, vaccine acceptability was nearly ubiquitous. However, characteristics such as cost, administration, and dosing could substantially impact uptake, as well as providers' accessibility and respect of confidentiality.
Planning of health education strategies, interventions, and programs
Public health or related research
Social and behavioral sciences
Identify factors that could affect uptake of future HIV vaccination among drug users
To discuss strategies of increasing future uptake of the HIV vaccine among drug users
Keyword(s): Immunizations, HIV/AIDS
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I am well-accomplished in the area of vaccine acceptance, including HIV vaccine acceptance. I have several peer-reviewed publications on this topic. Also, I am well-versed in the drug-using community used for this study -- my CDC-funded PRC is located in that same community.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.